4G16

Crystal structure of ck1g3 with 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2-YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE

Summary for 4G16

• Entry DOI: 10.2210/pdb4g16/pdb
• Related: 4G17
• Descriptor: Casein kinase I isoform gamma-3, 2-[(4-{[3-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)amino]-1H-benzimidazole-6-carbonitrile (3 entities in total)
• Functional Keywords: ck1g, kinase, inhibitor, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• Biological source: Homo sapiens (human)
• Cellular location: Cytoplasm: Q9Y6M4
• Total number of polymer chains: 1
• Total formula weight: 38864.56

Authors

Huang, X. (deposition date: 2012-07-10, release date: 2013-05-22, Last modification date: 2023-09-13)

Primary citation

Hua, Z.,Huang, X.,Bregman, H.,Chakka, N.,DiMauro, E.F.,Doherty, E.M.,Goldstein, J.,Gunaydin, H.,Huang, H.,Mercede, S.,Newcomb, J.,Patel, V.F.,Turci, S.M.,Yan, J.,Wilson, C.,Martin, M.W.
2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1g)inhibitors
Bioorg.Med.Chem.Lett., 22:5392-5395, 2012

PubMed Abstract: Screening of the Amgen compound library led to the identification of 2-phenylamino-6-cyano-1H-benzimidazole 1a as a potent CK1 gamma inhibitor with excellent kinase selectivity and unprecedented CK1 isoform selectivity. Further structure-based optimization of this series resulted in the discovery of 1h which possessed good enzymatic and cellular potency, excellent CK1 isoform and kinase selectivity, and acceptable pharmacokinetic properties.

PubMed: 22877629
DOI: 10.1016/j.bmcl.2012.07.046

Experimental method

X-RAY DIFFRACTION (2.3 Å)